AMX0035 and Progressive Supranuclear Palsy
← catalyst calendarSponsored by Amylyx Pharmaceuticals Inc. (industry) · AMLX — their whole pipeline →.
Phase
Phase 2/3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
139actual
Sites
62
Countries
France, Germany, Italy +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-21 | actual | When the study began enrolling |
| Primary completion | 2025-09-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-21 | actual | The whole study's end, after follow-up |
| First posted | 2023-11-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Progressive Supranuclear Palsy
- PSP
- Neurodegenerative Diseases
- Atypical Parkinsonism
Interventions
- Drug: AMX0035
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFChange in total (28-item) Progressive Supranuclear Palsy Rating Scale (PSPRS) Score
measured 52 weeks
Permalink · AMLX's whole pipeline · Catalyst calendar · Every registered study · What changed